Among the 1144 lung cancer samples analyzed, approximately 1.6% of them contained UBE2C changes, with a majority (1.13%) being gene amplification and approximately 2% of cases with UBE2S amplification (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI162434DS1). The gene discussed is UBE2C; the disease is lung carcinoma.